Jefferies (NYSE:JEF) analyst Michael Yee maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) on Sunday, setting a price target of $230, which is approximately 25.28%...
Berenberg Bank analyst Andrew Degasperi maintained a Buy rating on Vertex (NASDAQ:VRTX) on Tuesday, setting a price target of $27, which is approximately 43.01% above the present...
As the pharmaceutical sector continues to grow with rising chronic diseases and increased investments, we think it could be wise to scoop up the shares of cheap yet quality...
Vertex Pharmaceuticals Inc. (VRTX) specializes in discovering and manufacturing drugs for cystic fibrosis, an inherited disease with an average lifespan of around 44 years....
A number of health-care and biotech shares have recently been in the spotlight. In early October, Merck (NYSE:MRK)—covered in early November—gave a positive update on...
Myriad Genetics (NASDAQ:MYGN), Inc. MYGN is well poised for growth in the coming quarters on the ongoing strong recovery in testing volumes. The company’s recent launches of...
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; Mammoth Biosciences; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Neutral | Neutral | Sell |
| Technical Indicators | Sell | Strong Sell | Strong Sell | Neutral | Strong Sell |
| Summary | Sell | Strong Sell | Sell | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 165.30 | 165.52 | 159.92 | +5.06 | +3.16% | 168.32M | NASDAQ | |||
| 2,837.90 | 2,920.00 | 2,832.00 | -72.7 | -2.50% | 1.98M | NASDAQ | |||
| 324.46 | 335.81 | 323.43 | -13.57 | -4.01% | 24.94M | NASDAQ | |||
| 53.73 | 54.46 | 51.91 | +1.33 | +2.54% | 62.77M | NYSE | |||
| 127.53 | 131.32 | 126.13 | -4.08 | -3.10% | 32.18M | NYSE | |||
| 3,507.07 | 3,585.77 | 3,492.01 | -54.50 | -1.53% | 3.87M | NASDAQ | |||
| 74.91 | 75.03 | 73.84 | +0.02 | +0.03% | 28.20M | NYSE | |||
| 326.76 | 333.53 | 318.64 | -7.00 | -2.10% | 60.14M | NASDAQ | |||
| 18.59 | 18.83 | 18.52 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 172.39 | 174.22 | 165.96 | +2.06 | +1.21% | 5.98M | NYSE | |||
| 18.81 | 19.10 | 18.13 | 0.00 | 0.00% | 88.93K | NYSE | |||
| 65.67 | 69.07 | 65.54 | -3.61 | -5.21% | 70.95K | NYSE | |||
| 23.22 | 24.04 | 23.05 | -0.75 | -3.13% | 105.31K | NASDAQ | |||
| 52.45 | 53.63 | 52.44 | -1.71 | -3.16% | 29.64M | NYSE | |||
| 284.96 | 299.27 | 283.40 | -11.78 | -3.97% | 11.92M | NYSE |